DJO Has Completed the Acquisition of STAR Ankle and Finger Arthroplasty Systems

The acquisition includes the STAR® total ankle arthroplasty system, a preferred technology worldwide because of its deep and leading clinical outcomes research, along with Silicone, Surface Replacement, and TACTYS® finger joint arthroplasty products, one of the world’s most comprehensive finger joint arthroplasty portfolios.

November 12, 2020

DJO, LLC (DJO or the Company), a leading global provider of medical technologies to get and keep people moving, today announced that it has completed the acquisition of total ankle and finger arthroplasty product lines from international medical technology company Stryker.

DJO notes the acquisition includes the STAR® total ankle arthroplasty system, a preferred technology worldwide because of its deep and leading clinical outcomes research,1-9 along with Silicone, Surface Replacement (SR) and TACTYS® finger joint arthroplasty products, one of the world’s most comprehensive finger joint arthroplasty portfolios.

Ankle replacements in the U.S. more than doubled last year, in part because ankle implants are becoming the treatment of choice over fusion surgery.10 The STAR ankle is a mobile-bearing total ankle replacement in the U.S. market approved for uncemented use, making it a preferred choice for surgeons and patients who want to help restore mobility.

“Ankle and finger arthroplasty are two fast-growing arthroplasty segments, and this acquisition reflects DJO’s focus on providing market-leading solutions to meet the greater needs of surgeons and their patients,” said Brady Shirley, CEO of DJO®. “This expansion allows us to address a larger patient population and enhances our goal of helping patients return to an active lifestyle.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

April 30, 2025

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

April 24, 2025

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.